QuellTX
Madhav Kishore's work experience includes serving as a Principal Scientist at Quell Therapeutics since August 2022. Prior to this, they worked as a Senior Scientist at the same company from April 2021 to August 2022, and as a Scientist from July 2019 to March 2021.
Before joining Quell Therapeutics, Madhav worked as a Postdoctoral Researcher at UCL from March 2017 to June 2019, where they investigated cell-signalling and DNA-sensing mechanisms in immune cells related to autoimmune diseases such as rheumatoid arthritis and Lupus.
Madhav also worked as a Postdoctoral Researcher at the University of Leicester from January 2016 to February 2017, where they researched immune cells in chronic respiratory diseases and characterized different immune cell subtypes in patients with fungal-mediated lung tissue damage.
Madhav completed their PhD at Queen Mary University of London from October 2011 to January 2015, focusing on the role of co-stimulatory receptors in the regulation of T cell migration and its impact on transplantation and immunotherapy.
Lastly, they worked as an Immunology Researcher at Imperial College London from September 2009 to September 2011.
Madhav Kishore completed their education starting from 2002 to 2004 at Modern School, Barakhamba Road. The degree and field of study during this period are not specified. Later, they pursued a Master's degree in Bioscience Technology from the University of York, which they completed between 2007 and 2008. Finally, Madhav earned their doctoral degree in Immunology from Queen Mary University of London between 2011 and 2016.
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.